Hemophilia A is a hereditary bleeding disorder caused by deficiency of clotting Factor VIII, leading to painful joint bleeds, muscle bleeds, and potentially life-threatening bleeding with injuries or surgery. Gene therapy trials are bringing the possibility of a one-time cure closer to reality.
What's actually going on in research
Emicizumab, a bispecific antibody that mimics Factor VIII function without being a Factor VIII protein, has transformed prophylaxis by allowing subcutaneous weekly or monthly injections instead of IV infusions. Gene therapy delivering functional Factor VIII genes via viral vectors to liver cells has produced multi-year Factor VIII production in early trials, and one therapy is now approved. Non-factor therapy approaches including fitusiran (an anti-antithrombin agent) are being tested to reduce bleeding independent of the missing factor.
Emicizumab prophylaxis
Emicizumab bridges Factor IX and Factor X to substitute for Factor VIII function, dramatically reducing bleeds with subcutaneous dosing. Trials are testing it in infants, those with inhibitors, and new dosing schedules.
Gene therapy
Viral vector-delivered Factor VIII gene therapy has produced sustained factor levels for years in some patients. Trials are working on durability, consistency across patients, and use in younger individuals.
Non-factor hemostasis therapies
Fitusiran reduces anticoagulant activity to rebalance clotting without replacing the missing factor. Trials are testing it alongside emicizumab and in patients with inhibitors.
What to know before you search
Eligibility depends on hemophilia A severity (Factor VIII level), presence or absence of inhibitors, age, and prior treatment history.
What types of trials are currently open
- Prophylaxis trials — Testing new factor concentrates, extended half-life products, and bispecific antibodies for bleed prevention.
- Gene therapy trials — Evaluating viral vector gene delivery for long-term Factor VIII production and potential cure.
- Inhibitor management trials — Testing immune tolerance induction and non-factor therapies in patients who develop inhibitors.
- Joint health trials — Evaluating physical therapy, early prophylaxis, and surgical options for hemophilic arthropathy.
- Pediatric trials — Testing prophylaxis approaches and gene therapy in infants and young children.
Recently added Hemophilia A trials
Take an injection of a new gene therapy for bleeding disorders
The purpose of this study is to evaluate the safety, tolerability, immunogenicity , PK, and PD of a single dose of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors （Part A）and to evaluate the safety, PK, PD, and efficacy of multiple doses of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B and Part C).
Try light therapy sessions to reduce knee swelling from bleeding
Hemophilia is a genetic bleeding disorder that commonly leads to knee hemarthrosis, causing pain, swelling, and reduced joint mobility in children. While standard treatments include clotting factor replacement and physiotherapy, additional non-invasive approaches are being explored. This study aims to evaluate the effects of photobiomodulation on knee hemarthrosis in male hemophilia patients aged 9-14 years. It focuses on determining whether this therapy can reduce pain and swelling and improve joint range of motion when used alongside
Find Hemophilia A trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.